An AI-designed PET tracer targeting PARP-1, [68Ga]Ga-DOTA-FZPF, completed first-in-human evaluation in breast and ovarian cancer patients. Researchers said the AI-assisted design pipeline produced a tracer ready for clinical imaging, marking a step from computational discovery toward translational imaging biomarker development. For oncology imaging teams, first-in-human data are an essential milestone for assessing feasibility, biodistribution, and scan quality—parameters that determine whether the tracer can support patient selection or treatment monitoring. The program also signals continued convergence of AI-assisted chemistry design with precision oncology imaging endpoints.